← Back to Search

Pacemaker Implant

Micra Transcatheter Pacing System Continued Access Study Protocol

N/A
Waitlist Available
Research Sponsored by Medtronic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months post last follow up
Awards & highlights
No Placebo-Only Group

Summary

Medtronic is sponsoring the Micra Continued Access (CA) study to provide continued access to the Micra System while the marketing application is under review by the Food and Drug Administration (FDA).

Eligible Conditions
  • Bradycardia
  • Slow Heart Rate

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months post last follow up
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months post last follow up for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Complications

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Micra Pacemaker ImplantExperimental Treatment1 Intervention
Micra Pacemaker Implant
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Micra Pacemaker Implant
2013
N/A
~1030

Find a Location

Who is running the clinical trial?

MedtronicLead Sponsor
619 Previous Clinical Trials
763,803 Total Patients Enrolled
19 Trials studying Bradycardia
110,951 Patients Enrolled for Bradycardia
~27 spots leftby Dec 2025